Salud financiera de hoja de balance de Molecure

Salud financiera controles de criterios 4/6

Molecure tiene un patrimonio de los accionistas total de PLN80.1M y una deuda total de PLN0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son PLN87.7M y PLN7.6M respectivamente.

Información clave

Ratio deuda-patrimonio

zł0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	zł28.58m
Patrimonio	zł80.09m
Total pasivo	zł7.62m
Activos totales	zł87.71m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (PLN30.2M) de MOC superan a sus pasivos a corto plazo (PLN3.4M).

Pasivo a largo plazo: Los activos a corto plazo de MOC (PLN30.2M) superan a sus pasivos a largo plazo (PLN4.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: MOC está libre de deudas.

Reducción de la deuda: MOC no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MOC tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: MOC tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 13% cada año

Salud financiera de hoja de balance de Molecure

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera